ArticleWorld journal of urology2026
Risk factors and the impact of comorbidities in patients developing urethral stricture after transurethral resection of the prostate.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeUrethral stricture remains a clinically relevant complication after transurethral resection of the prostate (TURP). While procedural factors have been extensively studied, the contribution of systemic comorbidities to stricture development is less well defined. This study aimed to evaluate the association between common cardiovascular and metabolic comorbidities and urethral stricture formation following TURP.
methodsA retrospective cohort of 713 patients who underwent bipolar TURP for benign prostatic hyperplasia between January 2021 and January 2024 was analyzed. Urethral stricture was identified in 47 patients (6.6%). Propensity score matching (1:4) was performed based on age, prostate volume, operative time, and PSA levels, yielding a matched cohort of 235 patients. Comorbidities including smoking, hypertension, diabetes mellitus, dyslipidemia, and coronary artery disease (CAD) were assessed using clinical records and prescription data. Univariable and multivariable Cox proportional hazards regression analyses were performed to identify factors associated with time to urethral stricture development.
resultsIn the matched cohort, smoking, hypertension, CAD, and dyslipidemia were significantly more prevalent in patients who developed urethral stricture (all p < 0.05), whereas diabetes mellitus was not. In univariable Cox analysis, smoking (HR 2.13), hypertension (HR 2.76), CAD (HR 3.15), and dyslipidemia (HR 2.46) were significantly associated with an increased hazard of urethral stricture development. In multivariable Cox analysis, only CAD remained independently associated with the outcome (HR 2.06, 95% CI 1.02-4.16, p = 0.04). The most common stricture location was the bulbar urethra.
conclusionCoronary artery disease was independently associated with urethral stricture development following TURP. Other comorbidities may contribute through overlapping vascular and metabolic pathways. These findings highlight the importance of systemic disease burden when assessing postoperative stricture risk and planning perioperative management.
Indexed as
Identifiers
42149232What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.